Biologics, Inc. enters into definitive agreement to be acquired by McKesson Specialty Health

CARY, N.C. – February 25, 2016 – Biologics, Inc. is pleased to announce that the company has entered into a definitive agreement to be acquired by McKesson Specialty Health, a business unit of the McKesson Corporation. Biologics, an oncology pharmacy services company based in the Research Triangle, offers specialty pharmacy and patient support services specifically in the areas of oncology and other complex therapeutic categories.

“This is a historic moment for our company,” said Stuart Frantz, President and CEO of Biologics. “I am absolutely thrilled that our team will be joining the McKesson family, who shares our deep commitment to building a strong corporate culture focused on supporting people as individuals and providing better health. Our employees, patients, providers and clients will all benefit from the exceptional healthcare service platform, depth of talent and diverse capabilities the McKesson/Biologics partnership will provide.”

Thanks to a “people first” approach, Biologics has expanded its capabilities beyond commercial pharmaceutical distribution to include patient access and adherence services, growing its team by more than 400% in the past six years. As part of McKesson Specialty Health, Biologics will be able to serve more patients and providers through the McKesson Onmark provider offering as well as The US Oncology Network.

Following the acquisition’s close, both leadership teams will work together to integrate the organizations’ competencies in a way that best serves employees, patients, providers and clients. Biologics will continue to operate independently in Cary, North Carolina until close. Wells Fargo Securities served as exclusive financial advisor to Biologics in the transaction. Wyrick Robbins Yates & Ponton LLP served as legal counsel.


About Biologics, Inc.

Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payors and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk. For more information, visit


Media Contact
Allison Keenan
Director, Marketing & Communications
Biologics, Inc.